BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 15197149)

  • 1. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
    García Rodríguez LA; Varas-Lorenzo C; Maguire A; González-Pérez A
    Circulation; 2004 Jun; 109(24):3000-6. PubMed ID: 15197149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin.
    Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
    J Am Coll Cardiol; 2004 Mar; 43(6):985-90. PubMed ID: 15028354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
    Roumie CL; Choma NN; Kaltenbach L; Mitchel EF; Arbogast PG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
    van Staa TP; Rietbrock S; Setakis E; Leufkens HG
    J Intern Med; 2008 Nov; 264(5):481-92. PubMed ID: 18624902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada.
    Varas-Lorenzo C; Castellsague J; Stang MR; Perez-Gutthann S; Aguado J; Rodriguez LA
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1016-25. PubMed ID: 19718696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
    Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality.
    Bardia A; Ebbert JO; Vierkant RA; Limburg PJ; Anderson K; Wang AH; Olson JE; Vachon CM; Cerhan JR
    J Natl Cancer Inst; 2007 Jun; 99(11):881-9. PubMed ID: 17551148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction.
    Hudson M; Baron M; Rahme E; Pilote L
    J Rheumatol; 2005 Aug; 32(8):1589-93. PubMed ID: 16078339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
    Andersohn F; Suissa S; Garbe E
    Circulation; 2006 Apr; 113(16):1950-7. PubMed ID: 16618816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population.
    García Rodríguez LA; Tacconelli S; Patrignani P
    J Am Coll Cardiol; 2008 Nov; 52(20):1628-36. PubMed ID: 18992652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
    Hudson M; Rahme E; Richard H; Pilote L
    Arthritis Rheum; 2007 Apr; 57(3):516-23. PubMed ID: 17394181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.
    Schjerning Olsen AM; Fosbøl EL; Lindhardsen J; Folke F; Charlot M; Selmer C; Lamberts M; Bjerring Olesen J; Køber L; Hansen PR; Torp-Pedersen C; Gislason GH
    Circulation; 2011 May; 123(20):2226-35. PubMed ID: 21555710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.